Umeclidinium bromide

Umeclidinium bromide
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
Routes of
administration		Inhalation (DPI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~89%[3]
MetabolismLiver (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
Identifiers
  • Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.166.375
Chemical and physical data
FormulaC29H34BrNO2
Molar mass508.500 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]
  • InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
  • Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

Umeclidinium bromide, sold under the brand name Incruse Ellipta among others, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol),[5][6][7] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[8]

It is on the World Health Organization's List of Essential Medicines.[9] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10][11]

References

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
  3. ^ a b c "Incruse Ellipta- umeclidinium aerosol, powder". DailyMed. 13 December 2023. Retrieved 28 March 2025.
  4. ^ "Rolufta Ellipta (previously Rolufta)". European Medicines Agency (EMA). 20 March 2017. Retrieved 28 March 2025.
  5. ^ "Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 28 March 2025.
  6. ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
  7. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  8. ^ "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 28 March 2025.
  9. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  10. ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  11. ^ "Umeclidinium - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.